

除本公告另有界定外，本公告中所用詞彙與浙江同源康醫藥股份有限公司（「本公司」）所刊發日期為2024年8月12日的招股章程（「招股章程」）所界定者具有相同涵義。香港交易及結算所有限公司、香港聯合交易所有限公司（「香港聯交所」）及香港中央結算有限公司（「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州及哥倫比亞特區）發佈、發行、分派。本公告並非且不構成在美國或任何其他司法管轄區的任何銷售要約或購買或認購證券的招攬。發售股份未曾亦不會根據1933年美國證券法（經不時修訂）（「美國證券法」）或美國任何州的證券法登記。除非擁有有效登記聲明或獲豁免遵守美國證券法的登記規定或進行不受該證券法登記規定限制的交易，否則證券不得在美國提呈發售或出售。我們現時無意於美國公開發售證券。發售股份乃根據美國證券法S規例在美國境外以離岸交易方式發售及出售。

本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。有意投資者決定是否投資於H股前，應細閱招股章程以了解下文有關全球發售的詳細資料。



**TYK Medicines, Inc**  
**浙江同源康醫藥股份有限公司**  
(於中華人民共和國註冊成立的股份有限公司)  
(股份代號：2410)

## 澄清公告

本公司董事會（「董事會」）有意修改本公司刊發日期為2024年8月19日的最終發售價及配發結果公告（「配發結果公告」）中英文版本的若干手民之誤。

請參閱隨附顯示澄清的配發結果公告黑線版本。澄清詳情載於「禁售承諾」一節。

除隨附文件所顯示該等澄清外，配發結果公告所列的所有其他資料保持不變，且本公司確認配發結果公告並無任何重大錯誤陳述。

承董事會命  
浙江同源康醫藥股份有限公司  
董事長兼執行董事  
吳豫生博士

香港，2024年8月23日

於本公告日期，董事會成員包括：(i)執行董事吳豫生博士及蔣鳴昱博士；(ii)非執行董事李鈞博士、顧虹博士、孟曉英博士、何超先生及丁兆博士；及(iii)獨立非執行董事張森泉先生、冷瑜婷博士、許文青博士及沈秀華博士。

TYK MEDICINES, INC / 浙江同源康醫藥股份有限公司  
最終發售價及配發結果公告

除本公告另有界定者外，本公告所用詞彙與浙江同源康醫藥股份有限公司（「本公司」）所刊發日期為2024年8月12日的招股章程（「招股章程」）所界定者具有相同涵義。

警告：鑒於股權高度集中於數目不多之 H 股股東，即使少量 H 股成交，該公司之 H 股價格亦可能大幅波動，H 股股東及有意投資者於買賣該公司 H 股時務請審慎行事。

摘要

公司資料

股份代號	2410
股份簡稱	同源康醫藥-B
開始買賣日期	2024年8月20日*

\*請參閱本公告底部附註

價格資料

最終發售價	12.100 港元
發售價範圍	12.100 港元至 12.100 港元
進行發售價調整	否

發售股份及股本

發售股份數目	47,880,000
公開發售的發售股份數目(在重新分配後)	4,788,000
國際發售的發售股份數目(在重新分配後)	43,092,000
上市後已發行的股份數目	370,835,818

調整發售規模的選擇權

在發售規模調整選擇權下的額外股份數目	-
- 公開發售	-
- 國際發售	-

超額分配

超額分配的發售股份數目	-
-------------	---

所得款項

所得款項總額(附註)	579.35 百萬港元
減：基於最終發售價的估計應付上市開支	(73.04)百萬港元
所得款項淨額	506.31 百萬港元

附註：所得款項總額是指發行人有權收取的金額。有關所得款項用途的詳情，請參閱招股章程。

## 配發結果詳情

### 香港公開發售

有效申請數目	974
受理申請數目	649
認購額	2.29倍
重新分配	無
香港公開發售項下初步可供認購的發售股份數目	4,788,000
自國際發售重新分配的發售股份數目	0
公開發售項下最終發售股份數目(在重新分配後)	4,788,000
香港公開發售項下發售股份數目佔全球發售的百分比	10.00%

附註：有關向香港公開發售進行最終股份分配的詳情，投資者可以參考 [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) 以名稱或標識號進行搜索，或者訪問 [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) 以獲取獲分配者的完整列表。

### 國際發售

承配人的數量	116
認購額	1.01倍
國際發售項下初步可供認購的發售股份數目	43,092,000
重新分配至香港公開發售的發售股份數目	0
國際發售項下最終發售股份數目(在重新分配後)	43,092,000
國際發售項下發售股份數目佔全球發售的百分比	90.00%

董事確認，據彼等所深知、盡悉及確信，及聯交所就基石投資者長興興長（定義見下文）授出的豁免及同意除外，(i)承配人及公眾人士認購的發售股份並非由本公司、任何董事、監事、本公司最高行政人員、控股股東、主要股東、本公司現有股東或其任何附屬公司或彼等各自的緊密聯繫人直接或間接撥資、且(ii)購買發售股份的承配人及公眾人士概無習慣受本公司、任何董事、監事、本公司最高行政人員、控股股東、主要股東、本公司現有股東或其任何附屬公司或彼等各自的緊密聯繫人的指示而對登記於其名下或其以其他方式持有的股份進行收購、出售、表決或其他處置。

國際發售中的承配人包括以下各項：

#### 基石投資者

投資者	獲分配的發售股份數目	佔發售股份的百分比	佔全球發售後已發行H股總數的百分比	佔全球發售後已發行股本總額之百分比	現有股東或其緊密聯繫人
長興興長產業投資合夥企業（有限合夥）（「長興興長」）	17,000,000	35.51%	8.83%	4.58%	是#
總計	17,000,000	35.51%	8.83%	4.58%	

#### 獲豁免／同意的分配對象

投資者	獲分配的股份數目	佔發售股份的百分比	佔全球發售後已發行H股總數的百分比	佔全球發售後已發行股本總額之百分比	關係*
長興興長	17,000,000	35.51%	8.83%	4.58%	核心關連人士
總計	17,000,000	35.51%	8.83%	4.58%	

# 請參閱本公告「其他／附加信息」一節。

\*本公司已申請且聯交所已批准豁免嚴格遵守上市規則第 9.09(b) 及 10.04 條。向長興興長分配發售股份符合聯交所授予的所有條件。有關進一步詳情，請參閱招股章程「豁免嚴格遵守上市規則及豁免嚴格遵守公司（清盤及雜項條文）條例」一節。

#### 禁售承諾

#### 控股股東

姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
鄭州泰基鴻諾醫藥股份有限公司（「泰基鴻諾醫藥」） <small>附註1</small>	100,000,000 （包括35,000,000 H股及65,000,000 非上市股份）	18.17%	26.97%	2025年8月19日 <small>附註3</small>

長興利源企業管理合夥企業（有限合夥）（「長興利源」） <sup>附註2</sup>	22,670,000 （包括7,934,500 H股及14,735,500 非上市股份）	4.12%	6.11%	2025年8月19日 <sup>附註3</sup>
長興罌源企業管理合夥企業（有限合夥）（「長興罌源」） <sup>附註2</sup>	4,800,000 （包括1,680,000 H股及3,120,000非上市股份）	0.87%	1.29%	2025年8月19日 <sup>附註3</sup>
長興彩源企業管理合夥企業（有限合夥）（「長興彩源」） <sup>附註2</sup>	3,780,000 （包括1,323,000 H股及2,457,000非上市股份）	0.69%	1.02%	2025年8月19日 <sup>附註3</sup>
小計	131,250,000	23.85%	35.39%	

附註：

- (1) 泰基鴻諾醫藥實益擁有35,000,000股H股及65,000,000股非上市股份。泰基鴻諾醫藥分別由吳博士、鄭州鴻諾及鄭州德瑞持有約30.66%、20.15%及3.02%。鄭州鴻諾由其執行合夥人湖州德瑞管理，而湖州德瑞由吳博士擁有38.75%，鄭州德瑞擁有61%及本集團僱員之一張森先生擁有0.25%。鄭州德瑞由吳博士全資擁有。因此，根據證券及期貨條例，吳博士被視為於泰基鴻諾醫藥持有的35,000,000股H股及65,000,000股非上市股份中擁有權益。Zhu女士為吳博士的配偶。因此，根據證券及期貨條例，Zhu女士被視為於與吳博士擁有權益的相同股份數目中擁有權益。

(2) 長興利源實益擁有7,934,500股H股及14,735,500股非上市股份。長興利源由其執行合夥人鄭州德瑞（由吳博士全資擁有）管理。

長興彩源及長興罌源均為我們的員工持股計劃平台。長興彩源實益擁有1,323,000股H股及2,457,000股非上市股份。長興罌源實益擁有1,680,000股H股及3,120,000股非上市股份。長興彩源及長興罌源各自由其執行合夥人湖州德瑞管理，而湖州德瑞由吳博士擁有38.75%，鄭州德瑞擁有61%及本集團僱員之一張森先生擁有0.25%。鄭州德瑞由吳博士全資擁有。

因此，根據證券及期貨條例，吳博士被視為於(i)長興利源持有的7,934,500股H股及14,735,500股非上市股份；(ii)長興彩源持有的1,323,000股H股及2,457,000股非上市股份；及(iii)長興罌源持有的1,680,000股H股及3,120,000股非上市股份中擁有權益。

(3) 以上表格所示禁售期屆滿日期乃依據香港包銷協議及適用的中國法律。

### 首次公開發售前投資者（按招股章程「歷史、發展及公司架構」一節中的定義）

姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
寧波梅山保稅港區厚紀通諾投資管理合夥企業（有限合夥）（厚紀通諾） <sup>附註1</sup>	14,146,619 （包括4,951,317H股及9,195,302非上市股份）	2.57%	3.81%	2025年8月19日 <sup>附註7</sup>
長三角騰遠（長興）醫療股權投資合夥企業（有限合夥）（長三角騰遠）	12,600,000 （包括4,410,000H股及8,190,000非上市股份）	2.29%	3.40%	2025年8月19日 <sup>附註7</sup>
長興國海東湖股權投資合夥企業（有限合夥）（長興國海） <sup>附註2及6</sup>	12,185,600 （包括3,046,400H股及9,139,200非上市股份）	1.58%	3.29%	2025年8月19日 <sup>附註7</sup>



姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
四川匯宇製藥股份有限公司（匯宇製藥）	10,468,584 （包括3,664,004H股及6,804,580非上市股份）	1.90%	2.82%	2025年8月19日 <sup>附註7</sup>
長興興銀股權投資合夥企業（有限合夥）（長興興銀） <sup>附註3及6</sup>	10,015,305 （包括3,505,357H股及6,509,948非上市股份）	1.82%	2.70%	2025年8月19日 <sup>附註7</sup>
江蘇毅達成果創新創業投資基金（有限合夥）（毅達成果） <sup>附註4</sup>	9,600,000（H股）	4.98%	2.59%	2025年8月19日 <sup>附註7</sup>
成都博遠嘉昱創業投資合夥企業（有限合夥）（成都博遠）	9,201,568 （包括3,220,549H股及5,981,019股非上市股份）	1.67%	2.48%	2025年8月19日 <sup>附註7</sup>
江蘇中小企業發展基金（有限合夥）（江蘇中小企業） <sup>附註4</sup>	7,200,000（H股）	3.74%	1.94%	2025年8月19日 <sup>附註7</sup>
昆山華創毅達生醫股權投資企業（有限合夥）（華創毅達）	7,200,000（H股）	3.74%	1.94%	2025年8月19日 <sup>附註7</sup>
杭州三花弘道創業投資合夥企業（有限合夥）（三花弘道）	7,200,000（H股）	3.74%	1.94%	2025年8月19日 <sup>附註7</sup>
廈門融匯弘上股權投資合夥企業（有限合夥）（融匯弘上）	7,200,000 （包括2,520,000H股及4,680,000非上市股份）	1.31%	1.94%	2025年8月19日 <sup>附註7</sup>

姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
寧波複祺創業投資合夥企業（有限合夥）（複祺投資） <small>附註6</small>	7,200,000 （包括2,520,000H股及4,680,000非上市股份）	1.31%	1.94%	2025年8月19日 <small>附註7</small>
深圳揚子鑫康醫藥投資企業（有限合夥）（揚子鑫康）	6,259,566 （包括2,190,848H股及4,068,4718非上市股份）	1.14%	1.69%	2025年8月19日 <small>附註7</small>
株洲市國海國創千金醫藥創業投資合夥企業（有限合夥）（國海國創） <small>附註2</small>	6,144,000 （包括1,536,000H股及4,608,000非上市股份）	0.80%	1.66%	2025年8月19日 <small>附註7</small>
株洲市國創君和投資合夥企業（有限合夥）（國創君和） <small>附註5</small>	5,400,000 （包括1,890,000H股及3,510,000非上市股份）	0.98%	1.46%	2025年8月19日 <small>附註7</small>
寧波梅山保稅港區厚揚通馳投資管理合夥企業（有限合夥）（厚揚通馳） <small>附註1</small>	5,258,035 （包括1,840,312H股及3,417,723非上市股份）	0.96%	1.42%	2025年8月19日 <small>附註7</small>
湖州中金啟合股權投資合夥企業（有限合夥）（中金啟合） <small>附註6</small>	5,234,292（H股）	2.72%	1.41%	2025年8月19日 <small>附註7</small>
株洲市文周君喆創業投資合夥企業（有限合夥）（文周君喆） <small>附註5</small>	5,120,000 （包括1,792,000H股及3,328,000非上市股份）	0.93%	1.38%	2025年8月19日 <small>附註7</small>



姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
浙江絲路產業投資基金合夥企業（有限合夥）（浙江絲路）	5,007,653（H股）	2.60%	1.35%	2025年8月19日 <sup>附註7</sup>
湖南湘醫投同源壹號創業投資合夥企業（有限合夥）（湖南湘醫）	4,761,905 （包括1,666,667H股及3,095,238非上市股份）	0.87%	1.28%	2025年8月19日 <sup>附註7</sup>
杭州啟真未來創新股權投資合夥企業（有限合夥）（杭州啟真）	4,096,000（H股）	2.13%	1.10%	2025年8月19日 <sup>附註7</sup>
揚州澤康股權投資合夥企業（有限合夥）（揚州澤康）	3,655,575 （包括1,279,451H股及2,376,124非上市股份）	0.66%	0.99%	2025年8月19日 <sup>附註7</sup>
江蘇人才創新創業投資四期基金（有限合夥）（江蘇人才） <sup>附註4</sup>	3,600,000（H股）	1.87%	0.97%	2025年8月19日 <sup>附註7</sup>
長興鑫晟股權投資合夥企業（有限合夥）（長興鑫晟） <sup>附註3及6</sup>	3,140,575 （包括1,099,201H股及2,041,374非上市股份）	0.57%	0.85%	2025年8月19日 <sup>附註7</sup>
湖州海邦數湖創業投資合夥企業（有限合夥）（海邦數湖） <sup>附註6</sup>	3,072,000 （包括1,075,200H股及1,996,800非上市股份）	0.56%	0.83%	2025年8月19日 <sup>附註7</sup>
嘉興行仁股權投資合夥企業（有限合夥）（嘉興行仁）	2,380,952 （包括833,333H股及1,547,619非上市股份）	0.43%	0.64%	2025年8月19日 <sup>附註7</sup>

姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
吉愛寧先生	2,380,000 (包括833,000H股及1,547,000非上市股份)	0.43%	0.64%	2025年8月19日 <sup>附註7</sup>
嘉興望盈上和股權投資合夥企業(有限合夥)(望盈上和) <sup>附註6</sup>	1,884,160 (H股)	0.98%	0.51%	2025年8月19日 <sup>附註7</sup>
上海凱乘企業管理諮詢合夥企業(有限合夥)(上海凱乘)	720,000 (包括252,000H股及468,000非上市股份)	0.13%	0.19%	2025年8月19日 <sup>附註7</sup>
上海凡熹企業管理合夥企業(有限合夥)(上海凡熹) <sup>附註5</sup>	600,000 (包括210,000H股及390,000非上市股份)	0.11%	0.16%	2025年8月19日 <sup>附註7</sup>
湖州市人才創新股權投資基金合夥企業(有限合夥)(湖州人才) <sup>附註6</sup>	523,429 (H股)	0.27%	0.14%	2025年8月19日 <sup>附註7</sup>
小計	183,455,818	49.79%	49.47%	

附註：

- (1) 厚紀通諾及厚揚通馳將合共持有19,404,654股股份，佔上市後本公司已發行股本總額約5.23%。
- (2) 長興國海及國海國創將合共持有18,329,600股股份，佔上市後本公司已發行股本總額約4.94%。
- (3) 長興興銀及長興鑫晟將合共持有13,155,880股股份，佔上市後本公司已發行股本總額約3.55%。
- (4) 毅達成果、江蘇中小企業及江蘇人才將合共持有20,400,000股股份，佔上市後本公司已發行股本總額約5.50%。
- (5) 國創君和、文周君喆及上海凡熹將合共持有11,120,000股股份，佔上市後本公司已發行股本總額約3.00%。
- (6) 相關股東合夥權益的30%以上最終由浙江省人民政府監督管理。誠如招股章程「基石配售」一節進一步詳述，由浙江省人民政府監督管理的該等相關股東將合共持有43,255,361股股份，

姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
佔上市後本公司已發行股本總額約11.66%（並無計及最終亦由浙江省人民政府監督管理的基石投資者將予認購的股份）。				
(7) 以上表格所示禁售期屆滿日期乃依據適用的中國法律。				

現有股東（招股章程「歷史、發展及公司架構」一節中定義的首次公開發售前投資者除外）

姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
貝沃特醫藥技術（上海）有限公司（貝沃特醫藥）	8,250,000 （包括2,887,500H股及5,362,500非上市股份）	1.50%	2.22%	2025年8月19日
小計	8,250,000	1.50%	2.22%	
以上表格所示禁售期屆滿日期乃依據適用的中國法律。				

#### 基石投資者

姓名／名稱	上市後須遵守禁售承諾的本公司持股數目	上市後須遵守禁售承諾的全球發售後全部已發行H股百分比	上市後須遵守禁售承諾的本公司股權百分比	須遵守禁售承諾的最後一天
長興興長	17,000,000（H股）	8.83%	4.58%	2025年2月19日
小計	17,000,000	8.83%	4.58%	
基石投資者不得於所示日期或之前出售根據基石投資協議認購的任何發售股份。				

## 配售人集中度分析

配售人 <sup>(1)</sup>	獲配發H股數目	配發佔國際發售的百分比	配發佔發售股份總數的百分比	上市後所持股份數目 <sup>(2)</sup>	佔上市後已發行股本總額的百分比
最大	17,000,000	39.45%	35.51%	60,255,361	16.25%
前5	34,103,500	79.14%	71.23%	77,358,861	20.86%
前10	41,036,500	95.23%	85.71%	84,291,861	22.73%
前25	43,046,500	99.89%	89.90%	86,301,861	23.27%

### 附註

(1) 配售人排名基於配發給配售人的H股數量。

(2) 上市後所持股份數目包括現有股份。

## H股股東股權集中度分析

H股股東 <sup>(1)</sup>	獲配發H股數目	配發佔國際發售的百分比	配發佔發售股份總數的百分比	上市後所持H股數目	佔上市後已發行H股總數的百分比	上市後所持股份數目 <sup>(2)</sup>
最大	0	0.00%	0.00%	45,937,500	23.85%	131,250,000
前5	17,000,000	39.45%	35.51%	116,625,539	60.56%	226,305,361
前10	29,113,500	67.56%	60.81%	144,948,321	75.26%	275,431,168
前25	39,406,500	91.45%	82.30%	182,194,340	94.60%	356,881,366

附註：

(1) H股股東排名基於H股股東在上市後所持的H股數量。

(2) 上市後所持股份數目包括現有股份。

股權集中度分析

股東 <sup>(1)</sup>	獲配發H股數目	配發佔國際發售的百分比	配發佔發售股份總數的百分比	上市後所持股份數目 <sup>(2)</sup>	佔上市後已發行股本總額的百分比
最大	0	0.00%	0.00%	131,250,000	35.39%
前5	17,000,000	39.45%	35.51%	243,910,015	65.77%
前10	17,000,000	39.45%	35.51%	290,150,167	78.24%
前25	36,543,500	84.80%	76.32%	358,779,318	96.75%

附註

(1) 股東排名基於股東在上市後所持的（所有類別）股份數量。

(2) 上市後所持股份數目包括現有股份。

### 香港公開發售的分配準則

招股章程所載的條件獲達成後，公眾提出的974份有效申請將按下列準則有條件分配：

甲組：

所申請 H 股數目	有效申 請數目	配發／抽 籤基準	獲配發 H 股佔所申請總數的 概約百分比
500	614	614 名中 294 名獲發 500 股股份	47.88%
1,000	117	117 名中 112 名獲發 500 股股份	47.86%
1,500	37	500 股股份加上 37 名中 16 名獲發額外 500 股股份	47.75%
2,000	36	500 股股份加上 36 名中 32 名獲發額外 500 股股份	47.22%
2,500	18	1,000 股股份加上 18 名中 6 名獲發額外 500 股股份	46.67%
3,000	19	1,000 股股份加上 19 名中 15 名獲發額外 500 股股份	46.49%
3,500	8	1,500 股股份加上 8 名中 2 名獲發額外 500 股股份	46.43%
4,000	20	1,500 股股份加上 20 名中 14 名獲發額外 500 股股份	46.25%
4,500	1	2,000 股股份	44.44%
5,000	23	2,000 股股份加上 23 名中 10 名獲發額外 500 股股份	44.35%
6,000	5	2,500 股股份加上 5 名中 1 名獲發額外 500 股股份	43.33%
7,000	2	3,000 股股份	42.86%
8,000	7	3,000 股股份加上 7 名中 5 名獲發額外 500 股股份	41.96%
9,000	7	3,500 股股份加上 7 名中 2 名獲發額外 500 股股份	40.48%
10,000	18	4,000 股股份	40.00%
15,000	3	6,000 股股份	40.00%



所申請 H 股數目	有效申 請數目	配發／抽 籤基準	獲配發 H 股佔所申請總數的 概約百分比
20,000	5	8,000 股股份	40.00%
25,000	3	10,000 股股份	40.00%
30,000	3	12,000 股股份	40.00%
50,000	3	20,000 股股份	40.00%
60,000	1	24,000 股股份	40.00%
70,000	1	28,000 股股份	40.00%
80,000	1	31,500 股股份	39.38%
90,000	1	35,000 股股份	38.89%
100,000	5	38,500 股股份	38.50%
200,000	4	76,500 股股份加上 4 名中 3 名 獲發額外 500 股股份	38.44%
300,000	5	115,000 股股份加上 5 名中 3 名 獲發額外 500 股股份	38.43%
400,000	3	153,500 股股份加上 3 名中 1 名 獲發額外 500 股股份	38.42%
總計	970	甲組獲接納申請人總數：645	

## 乙組

所申請 H 股數目	有效申 請數目	配發／抽 籤基準	獲配發 H 股佔所申請總數的 概約百分比
500,000	1	240,000 股股份	48.00%
1,250,000	1	598,500 股股份	47.88%
1,500,000	1	718,000 股股份	47.87%
1,750,000	1	837,500 股股份	47.86%
總計	4	乙組獲接納申請人總數：4	

截至本公告日期，此前存放於指定代理人戶口的相關認購款項已匯回至所有香港結算參與者的賬戶。投資者如有任何查詢，請聯絡其相關經紀。

### 遵守上市規則和指引

董事確認，除上市規則已獲豁免及／或已取得同意外，本公司已遵守有關H股配售、配發及上市的上市規則及指引。

董事確認，就彼等所知，除任何經紀佣金、會財局交易徵費、證監會交易徵費及應付交易費外，配售人或公眾人士（視情況而定）直接或間接就彼等認購或購買的每股發售股份支付的代價與最終發售價相同。

### 其他／附加信息

本公司已向聯交所申請，且聯交所已向本公司授出豁免及上市規則第 9.09(b)條及第 10.04 條規定及配售指引第 5(2)段的同意，允許長興興長作為基石投資者在全球發售中認購 H 股。由於湖州人才、長興興銀、長興鑫晟、中金啟合、長興國海、海邦數湖、望盈上和及複祺投資（現有股東，統稱「浙江相關實體」）各自合夥權益的 30%以上最終由浙江省人民政府監督管理，且浙江相關實體於上市後將合計持有 43,255,361 股股份（即本公司已發行股本總額的約 11.66%），故被視為本公司的核心關連人士。長興興長為一家由長興縣人民政府（為浙江省的一個縣政府）監督管理的實體。有關詳情，請參閱「豁免嚴格遵守上市規則及豁免嚴格遵守公司（清盤及雜項條文）條例－核心關連人士在上市申請過程中進行基石認購」一節。

## 免責聲明

香港交易及結算所有限公司、香港聯合交易所有限公司（「**聯交所**」）及香港中央結算有限公司（「**香港結算**」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本公告不會直接或間接於或向美國（包括美國的領土及屬地、任何州以及哥倫比亞特區）發佈、刊發、分發。本公告並不構成或組成在美國購買或認購證券的任何要約或招攬的一部分。本公告所述證券並無亦不會根據1933年美國證券法（經修訂）（「**美國證券法**」）登記。除非證券已獲豁免美國證券法的登記規定並符合任何適用州證券法，否則不得在美國提呈發售或出售；或除非符合美國證券法S規例，否則不得在美國境外提呈發售或出售。證券將不會在美國公開發售。

發售股份根據美國證券法S規例以離岸交易方式在美國境外提呈發售及出售。

本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。潛在投資者在決定是否投資所提呈發售股份前，務請細閱浙江同源康醫藥股份有限公司所刊發日期為2024年8月12日的招股章程，以了解下文所述有關全球發售的詳細資料。

發售股份的潛在投資者務請注意，整體協調人（為其本身及代表香港包銷商）有權在招股章程「包銷—2.包銷安排及開支—香港公開發售—終止理由」一段所載的任何事件發生後，於上市日期（目前預期為2024年8月20日）上午八時正（香港時間）之前隨時即時終止彼等於香港包銷協議項下的責任。

## 公眾持股量

緊隨全球發售完成後，(i)經計及首次公開發售前投資者及現有股東將獲發行及持有的144,706,173股從未上市股份轉換的H股，93,007,501股H股（佔已發行股份總數的25.08%）將由公眾持有，符合上市規則第8.08(1)條項下的最低百分比規定；(ii)根據上市規則第8.08(3)及8.24條，上市時由公眾人士持有的股份中，由持股量最高的三名公眾股東擁有的百分比，不會超過50%；及(iii)根據上市規則第8.08(2)條，於上市時股東人數將至少為300人。

董事確認，緊隨全球發售完成後，(i)概無配售人可單獨獲配售本公司經擴大已發行股本之10%以上；及(ii)本公司將不會有任何新主要股東（定義見上市規則）。

## 開始買賣

僅於全球發售已成為無條件且「包銷—2.包銷安排及開支—香港公開發售—終止理由」所述終止權利未獲行使的情況下，H股股票方會於2024年8月20日（星期二）上午八時正（香港時間）成為有效所有權憑證。倘投資者在獲發H股股票前或在H股股票成為有效的所有權憑證前按照公開的分配詳情買賣股份，須自行承擔一切風險。

假設香港公開發售於2024年8月20日（星期二）上午八時正（香港時間）或之前成為無條件，則預期H股將於2024年8月20日（星期二）上午九時正（香港時間）開始在聯交所買賣。H股

將以每手500股H股進行買賣，H股的股份代號將為2410。

承董事會命  
浙江同源康醫藥股份有限公司  
董事長、執行董事兼總裁  
吳豫生博士

香港，2024年8月19日

截至本公告日期，執行董事為吳豫生博士及蔣鳴昱博士，非執行董事為李鈞博士、顧虹博士、孟曉英博士、何超先生及丁兆博士，獨立非執行董事為張森泉先生、冷瑜婷博士、許文青博士及沈秀華博士。

**TYK MEDICINES, INC / 浙江同源康醫藥股份有限公司**  
**ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT**  
**RESULTS**

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 12 August 2024 (the “**Prospectus**”) issued by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”).

**Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.**

**SUMMARY**

**Company Information**

<b>Stock code</b>	2410
<b>Stock short name</b>	TYK MEDICINES-B
<b>Dealings commencement date</b>	20 August 2024*

\*see note at the end of the announcement

**Price Information**

<b>Final Offer Price</b>	HK\$12.100
<b>Offer Price Range</b>	HK\$12.100 - HK\$12.100
<b>Offer Price Adjustment exercised</b>	No

**Offer Shares and Share Capital**

<b>Number of Offer Shares</b>	47,880,000
<b>Number of Offer Shares in Public Offer (after reallocation)</b>	4,788,000
<b>Number of Offer Shares in International Offer (after reallocation)</b>	43,092,000
<b>Number of issued shares upon Listing</b>	370,835,818

**Offer Size Adjustment Option (Upsize option)**

<b>Number of additional shares issued under the option</b>	-
- <b>Public Offer</b>	-
- <b>International Offer</b>	-

**Over-allocation**

<b>No. of Offer Shares over-allocated</b>	-
---	---

**Proceeds**

<b>Gross proceeds (Note)</b>	HK\$ 579.35 million
<b>Less: Estimated listing expenses payable based on Final Offer Price</b>	HK\$ (73.04) million
<b>Net proceeds</b>	HK\$ 506.31 million

*Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the Prospectus.*

## ALLOTMENT RESULTS DETAILS

### HONG KONG PUBLIC OFFERING

<b>No. of valid applications</b>	974
<b>No. of successful applications</b>	649
<b>Subscription level</b>	2.29 times
<b>Re-allocation</b>	No
<b>No. of Offer Shares initially available under the Hong Kong Public Offering</b>	4,788,000
<b>No. of Offer Shares reallocated from the International Offering</b>	0
<b>Final no. of Offer Shares under the Public Offer (after reallocation)</b>	4,788,000
<b>% of Offer Shares under the Hong Kong Public Offering to the Global Offering</b>	10.00%

*Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) to perform a search by name or identification number or [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) for the full list of allottees.*

### INTERNATIONAL OFFERING

<b>No. of places</b>	116
<b>Subscription Level</b>	1.01 times
<b>No. of Offer Shares initially available under the International Offering</b>	43,092,000
<b>No. of Offer Shares reallocated to the Hong Kong Public Offering</b>	0
<b>Final no. of Offer Shares under the International Offering (after reallocation)</b>	43,092,000
<b>% of Offer Shares under the International Offering to the Global Offering</b>	90.00%

*The Directors confirm that, to the best of their knowledge, information and belief, and save as the waiver and consent for Changxing Xingchang (as defined below) as a Cornerstone Investor granted by the Stock Exchange, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

The places in the International Offering include the following:

**Cornerstone Investor**

<b>Investor</b>	<b>No. of Offer Shares allocated</b>	<b>% of Offer Shares</b>	<b>% of total issued H Shares after the Global Offering</b>	<b>% of total issued share capital after the Global Offering</b>	<b>Existing shareholders or their close associates</b>
Changxing Xingchang Industrial Investment Partnership (Limited Partnership) / 長興興長產業投資合夥企業 (有限合夥) (“Changxing Xingchang”)	17,000,000	35.51%	8.83%	4.58%	Yes <sup>#</sup>
Total	17,000,000	35.51%	8.83%	4.58%	

**Allottee with waivers/consents obtained**

<b>Investor</b>	<b>No. of shares allocated</b>	<b>% of offer shares</b>	<b>% of total issued H Shares after the Global Offering</b>	<b>% of total issued share capital after the Global Offering</b>	<b>Relationship*</b>
Changxing Xingchang	17,000,000	35.51%	8.83%	4.58%	Core connected person
Total	17,000,000	35.51%	8.83%	4.58%	

# Please refer to the section headed “Others / Additional Information” in this announcement.

\*The Company has applied for, and the Stock Exchange has granted, a waiver from strict compliance with Rules 9.09(b) and 10.04 of the Listing Rules. The allocation of Offer Shares to Changxing Xingchang is in compliance with all the conditions under the consent granted by the Stock Exchange. Please refer to the “Waivers from Strict Compliance with Listing Rules and Exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” section in the Prospectus for further details.



## LOCK-UP UNDERTAKINGS

### Controlling Shareholders

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Tetranov Pharmaceutical (Zhengzhou) Co., Ltd. / 鄭州泰基鴻諾醫藥股份有限公司 (“ <b>Tetranov Pharmaceutical</b> ”) <sup>Note 1</sup>	100,000,000 (including 35,000,000 H Shares and 65,000,000 Unlisted Shares)	18.17%	26.97%	19 August 2025 <sup>Note 3</sup>
Changxing Liyuan Enterprise Management Partnership (Limited Partnership) / 長興利源企業管理合夥企業(有限合伙) (“ <b>Changxing Liyuan</b> ”) <sup>Note 2</sup>	22,670,000 (including 7,934,500 H Shares and 14,735,500 Unlisted Shares)	4.12%	6.11%	19 August 2025 <sup>Note 3</sup>
Changxing Gangyuan Enterprise Management Partnership (Limited Partnership) / 長興罡源企業管理合夥企業(有限合伙) (“ <b>Changxing Gangyuan</b> ”) <sup>Note 2</sup>	4,800,000 (including 1,680,000 H Shares and 3,120,000 Unlisted Shares)	0.87%	1.29%	19 August 2025 <sup>Note 3</sup>

Changxing Caiyuan Enterprise Management Partnership (Limited Partnership) / 長興彩源企業管理合夥企業(有限合夥) (“Changxing Caiyuan”) <sup>Note 2</sup>	3,780,000 (including 1,323,000 (H Shares and 2,457,000 Unlisted Shares)	0.69%	1.02%	19 August 2025 <sup>Note 3</sup>
Subtotal	131,250,000	23.85%	35.39%	

*Notes:*

(1) *Tetranov Pharmaceutical beneficially owns 35,000,000 H Shares and 65,000,000 Unlisted Shares. Tetranov Pharmaceutical is held as to approximately 30.66% by Dr. Wu, approximately 20.15% by Zhengzhou Hongnuo and approximately 3.02% by Zhengzhou Derui, respectively. Zhengzhou Hongnuo is managed by its executive partner, Huzhou Derui, which is owned as to 38.75% by Dr. Wu, 61% by Zhengzhou Derui and 0.25% by Mr. ZHANG Sen (張森), one of the Group’s employees. Zhengzhou Derui is wholly owned by Dr. Wu. As such, under the SFO, Dr. Wu is deemed to be interested in the 35,000,000 H Shares and 65,000,000 Unlisted Shares held by Tetranov Pharmaceutical. Ms. Zhu is spouse of Dr. Wu. Therefore, under the SFO, Ms. Zhu is deemed to be interested in the same number of Shares in which Dr. Wu is interested in.*

(2) *Changxing Liyuan beneficially owns 7,934,500 H Shares and 14,735,500 Unlisted Shares. Changxing Liyuan is managed by its executive partner, Zhengzhou Derui, which is wholly owned by Dr. Wu.*

*Each of Changxing Caiyuan and Changxing Gangyuan is the ESOP Platform. Changxing Caiyuan beneficially owns 1,323,000 H Shares and 2,457,000 Unlisted Shares. Changxing Gangyuan beneficially owns 1,680,000 H Shares and 3,120,000 Unlisted Shares. Each of Changxing Caiyuan and Changxing Gangyuan is managed by its executive partner, Huzhou Derui, which is owned as to 38.75% by Dr. Wu, 61% by Zhengzhou Derui and 0.25% by Mr. ZHANG Sen (張森), one of the Group’s employees. Zhengzhou Derui is wholly owned by Dr. Wu.*

*As such, under the SFO, Dr. Wu is deemed to be interested in (i) the 7,934,500 H Shares and 14,735,500 Unlisted Shares held by Changxing Liyuan; (ii) the 1,323,000 H Shares and 2,457,000 Unlisted Shares held by Changxing Caiyuan; and (iii) the 1,680,000 H Shares and 3,120,000 Unlisted Shares held by Changxing Gangyuan.*

(3) *The expiry date of the lock-up period shown in the table above is pursuant to the Hong Kong Underwriting Agreement and the applicable PRC laws.*

**Pre-IPO Investors (as defined in the “History, Development and Corporate Structure” section of the Prospectus)**

<b>Name</b>	<b>Number of shares held in the Company subject to lock-up undertakings upon Listing</b>	<b>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</b>	<b>% of shareholding in the Company subject to lock-up undertakings upon Listing</b>	<b>Last day subject to the lock-up undertakings</b>
Ningbo Meishan Bonded Port Area Houji Tongnuo Investment Management Partnership (Limited Partnership) / 寧波梅山保稅港區厚紀通諾投資管理合夥企業(有限合夥) (Houji Tongnuo) <sup>Note 1</sup>	14,146,619 (including 4,951,317 H Shares and 9,195,302 Unlisted Shares)	2.57%	3.81%	19 August 2025 <sup>Note 7</sup>
Changsanjiao Tengyuan (Changxing) Medical Equity Investment Partnership (Limited Partnership) / 長三角騰遠(長興)醫療股權投資合夥企業(有限合夥) (Changsanjiao Tengyuan)	12,600,000 (including 4,410,000 H Shares and 8,190,000 Unlisted Shares)	2.29%	3.40%	19 August 2025 <sup>Note 7</sup>
Changxing Guohai Donghu Equity Investment Partnership (Limited Partnership) / 長興國海東湖股權投資合夥企業(有限合夥) (Changxing Guohai) <sup>Notes 2 &amp; 6</sup>	12,185,600 (including 3,046,400 H Shares and 9,139,200 Unlisted Shares)	1.58%	3.29%	19 August 2025 <sup>Note 7</sup>
Sichuan Huiyu Pharmaceutical Co., Ltd. / 四川匯宇製藥股份有限公司 (Huiyu Pharmaceutical)	10,468,584 (including 3,664,004 H Shares and 6,804,580 Unlisted Shares)	1.90%	2.82%	19 August 2025 <sup>Note 7</sup>
Changxing Xingyin Equity Investment Partnership (Limited Partnership) / 長興興銀股權投資合夥企業(有限合夥) (Changxing Xingyin) <sup>Notes 3 &amp; 6</sup>	10,015,305 (including 3,505,357 H Shares and 6,509,948 Unlisted Shares)	1.82%	2.70%	19 August 2025 <sup>Note 7</sup>

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Jiangsu Addor Capital Results Innovation Venture Capital Fund (Limited Partnership) / 江蘇毅達成果創新創業投資基金(有限合夥) (Addor Results) <sup>Note 4</sup>	9,600,000 (H Shares)	4.98%	2.59%	19 August 2025 <sup>Note 7</sup>
Chengdu Boyuan Jiayu Venture Capital Partnership (Limited Partnership) / 成都博遠嘉昱創業投資合夥企業(有限合夥) (Chengdu Boyuan)	9,201,568 (including 3,220,549 H Shares and 5,981,019 Unlisted Shares)	1.67%	2.48%	19 August 2025 <sup>Note 7</sup>
Jiangsu Small and Medium Enterprises Development Fund (Limited Partnership) / 江蘇中小企業發展基金(有限合夥) (Jiangsu SME) <sup>Note 4</sup>	7,200,000 (H Shares)	3.74%	1.94%	19 August 2025 <sup>Note 7</sup>
Kunshan Huachuang Yida Biomedical Equity Investment Enterprise (Limited Partnership) / 昆山華創毅達生醫股權投資企業(有限合夥) (Huachuang Yida)	7,200,000 (H Shares)	3.74%	1.94%	19 August 2025 <sup>Note 7</sup>
Hangzhou Sanhua Hongdao Venture Capital Partnership (Limited Partnership) / 杭州三花弘道創業投資合夥企業(有限合夥) (Sanhua Hongdao)	7,200,000 (H Shares)	3.74%	1.94%	19 August 2025 <sup>Note 7</sup>

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Xiamen Ronghui Hongshang Equity Investment Partnership (Limited Partnership) / 廈門融匯弘上股權投資合夥企業(有限合夥) (Ronghui Hongshang)	7,200,000 (including 2,520,000 H Shares and 4,680,000 Unlisted Shares)	1.31%	1.94%	19 August 2025 <sup>Note 7</sup>
Ningbo Fuqi Venture Capital Partnership (Limited Partnership) / 寧波複祺創業投資合夥企業(有限合夥) (Fuqi Investment) <sup>Note 6</sup>	7,200,000 (including 2,520,000 H Shares and 4,680,000 Unlisted Shares)	1.31%	1.94%	19 August 2025 <sup>Note 7</sup>
Shenzhen Yangzi Xinkang Pharmaceutical Investment Enterprise (Limited Partnership) / 深圳揚子鑫康醫藥投資企業(有限合夥) (Yangzi Xinkang)	6,259,566 (including 2,190,848 H Shares and 4,068,718 Unlisted Shares)	1.14%	1.69%	19 August 2025 <sup>Note 7</sup>
Zhuzhou Guohai Guochuang Qianjin Pharmaceutical Venture Capital Partnership (Limited Partnership) / 株洲市國海國創千金醫藥創業投資合夥企業(有限合夥) (Guohai Guochuang) <sup>Note 2</sup>	6,144,000 (including 1,536,000 H Shares and 4,608,000 Unlisted Shares)	0.80%	1.66%	19 August 2025 <sup>Note 7</sup>
Zhuzhou Guochuang Junhe Investment Partnership (Limited Partnership) / 株洲市國創君和投資合夥企業(有限合夥) (Guochuang Junhe) <sup>Note 5</sup>	5,400,000 (including 1,890,000 H Shares and 3,510,000 Unlisted Shares)	0.98%	1.46%	19 August 2025 <sup>Note 7</sup>

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Ningbo Meishan Bonded Port Area Houyang Tongchi Investment Management Partnership (Limited Partnership) / 寧波梅山保稅港區厚揚通馳投資管理合夥企業(有限合夥) (Houyang Tongchi) <sup>Note 1</sup>	5,258,035 (including 1,840,312 H Shares and 3,417,723 Unlisted Shares)	0.96%	1.42%	19 August 2025 <sup>Note 7</sup>
Huzhou Zhongjin Qihe Equity Investment Partnership (Limited Partnership) / 湖州中金啟合股權投資合夥企業(有限合夥) (CICC Qihe) <sup>Note 6</sup>	5,234,292 (H Shares)	2.72%	1.41%	19 August 2025 <sup>Note 7</sup>
Zhuzhou Wenzhou Junzhe Venture Capital Partnership (Limited Partnership) / 株洲市文周君喆創業投資合夥企業(有限合夥) (Wenzhou Junzhe) <sup>Note 5</sup>	5,120,000 (including 1,792,000 H Shares and 3,328,000 Unlisted Shares)	0.93%	1.38%	19 August 2025 <sup>Note 7</sup>
Zhejiang Silk Road Industrial Investment Fund Partnership (Limited Partnership) / 浙江絲路產業投資基金合夥企業(有限合夥) (Zhejiang Silk Road)	5,007,653 (H Shares)	2.60%	1.35%	19 August 2025 <sup>Note 7</sup>
Hunan Xiangyi Investment Tongyuan No. 1 Venture Capital Partnership (Limited Partnership) / 湖南湘醫投同源壹號創業投資合夥企業(有限合夥) (Hunan Xiangyi)	4,761,905 (including 1,666,667 H Shares and 3,095,238 Unlisted Shares)	0.87%	1.28%	19 August 2025 <sup>Note 7</sup>

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Hangzhou Qizhen Future Innovation Equity Investment Partnership (Limited Partnership) / 杭州啟真未來創新股權投資合夥企業(有限合夥) (Hangzhou Qizhen)	4,096,000 (H Shares)	2.13%	1.10%	19 August 2025 <sup>Note 7</sup>
Yangzhou Zekang Equity Investment Partnership (Limited Partnership) / 揚州澤康股權投資合夥企業(有限合夥) (Yangzhou Zekang)	3,655,575 (including 1,279,451 H Shares and 2,376,124 Unlisted Shares)	0.66%	0.99%	19 August 2025 <sup>Note 7</sup>
Jiangsu Talent Innovation Venture Capital Fund IV (Limited Partnership) / 江蘇人才創新創業投資四期基金(有限合夥) (Jiangsu Talent) <sup>Note 4</sup>	3,600,000 (H Shares)	1.87%	0.97%	19 August 2025 <sup>Note 7</sup>
Changxing Xinsheng Equity Investment Partnership (Limited Partnership) / 長興鑫晟股權投資合夥企業(有限合夥) (Changxing Xinsheng) <sup>Notes 3 &amp; 6</sup>	3,140,575 (including 1,099,201 H Shares and 2,041,374 Unlisted Shares)	0.57%	0.85%	19 August 2025 <sup>Note 7</sup>
Huzhou Haibang Shuhu Venture Capital Partnership (Limited Partnership) / 湖州海邦數湖創業投資合夥企業(有限合夥) (Haibang Shuhu) <sup>Note 6</sup>	3,072,000 (including 1,075,200 H Shares and 1,996,800 Unlisted Shares)	0.56%	0.83%	19 August 2025 <sup>Note 7</sup>



<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Jiaxing Xingren Equity Investment Partnership (Limited Partnership) / 嘉興行仁股權投資合夥企業(有限合夥) (Jiaxing Xingren)	2,380,952 (including 833,333 H Shares and 1,547,619 Unlisted Shares)	0.43%	0.64%	19 August 2025 <sup>Note 7</sup>
Mr. JI Aining / 吉愛寧	2,380,000 (including 833,000 H Shares and 1,547,000 Unlisted Shares)	0.43%	0.64%	19 August 2025 <sup>Note 7</sup>
Jiaxing Wangying Shanghe Equity Investment Partnership (Limited Partnership) / 嘉興望盈上和股權投資合夥企業(有限合夥) (Wangying Shanghe) Note 6	1,884,160 (H Shares)	0.98%	0.51%	19 August 2025 <sup>Note 7</sup>
Shanghai Kaicheng Enterprise Management Consulting Partnership (Limited Partnership) / 上海凱乘企業管理諮詢合夥企業(有限合夥) (Shanghai Kaicheng)	720,000 (including 252,000 H Shares and 468,000 Unlisted Shares)	0.13%	0.19%	19 August 2025 <sup>Note 7</sup>
Shanghai Fanxi Enterprise Management Partnership (Limited Partnership) / 上海凡熹企業管理合夥企業(有限合夥) (Shanghai Fanxi) <sup>Note 5</sup>	600,000 (including 210,000 H Shares and 390,000 Unlisted Shares)	0.11%	0.16%	19 August 2025 <sup>Note 7</sup>
Huzhou Talent Innovation Equity Investment Fund	523,429 (H Shares)	0.27%	0.14%	19 August 2025 <sup>Note 7</sup>

<b>Name</b>	<b>Number of shares held in the Company subject to lock-up undertakings upon Listing</b>	<b>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</b>	<b>% of shareholding in the Company subject to lock-up undertakings upon Listing</b>	<b>Last day subject to the lock-up undertakings</b>
Partnership (Limited Partnership) / 湖州市人才創新股權投資基金合夥企業(有限合夥) (Huzhou Talent) <sup>Note 6</sup>				
<b>Subtotal</b>	183,455,818	49.79%	49.47%	

*Notes:*

- (1) Houji Tongnuo and Houyang Tongchi in aggregate will hold 19,404,654 Shares which represent approximately 5.23% of the total issued share capital of the Company upon Listing.
- (2) Changxing Guohai and Guohai Guochuang in aggregate will hold 18,329,600 Shares which represent approximately 4.94% of the total issued share capital of the Company upon Listing.
- (3) Changxing Xingyin and Changxing Xinsheng in aggregate will hold 13,155,880 Shares approximately 3.55% of the total issued share capital of the Company upon Listing.
- (4) Addor Results, Jiangsu SME and Jiangsu Talent in aggregate will hold 20,400,000 Shares which represent approximately 5.50% of the total issued share capital of the Company upon Listing.
- (5) Guochuang Junhe, Wenzhou Junzhe and Shanghai Fanxi in aggregate will hold 11,120,000 Shares which represent approximately 3.00% of the total issued share capital of the Company upon Listing.
- (6) More than 30% of the partnership interest of the relevant Shareholder is ultimately under the supervision and management of Zhejiang Provincial People's Government. Such relevant Shareholders under the supervision and management of Zhejiang Provincial People's Government will in aggregate hold 43,255,361 Shares which represent approximately 11.66% of the total issued share capital of the Company upon Listing, without taking into account the Shares to be subscribed by the cornerstone investor that is also ultimately under the supervision and management of Zhejiang Provincial People's Government, as further described in the section headed "Cornerstone Placing" in the Prospectus.
- (7) The expiry date of the lock-up period shown in the table above is pursuant to the applicable PRC laws.

**Existing Shareholder (other than the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)**

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Pivot Pharma Tech (Shanghai) Co., Ltd. / 貝沃特醫藥技術(上海)有限公司 (Pivot Pharma)	8,250,000 (including 2,887,500 H Shares and 5,362,500 Unlisted Shares)	1.50%	2.22%	19 August 2025
Subtotal	8,250,000	1.50%	2.22%	

*The expiry date of the lock-up period shown in the table above is pursuant to the applicable PRC laws.*

**Cornerstone Investor**

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Changxing Xingchang	17,000,000 (H Shares)	8.83%	4.58%	19 February 2025
Subtotal	17,000,000	8.83%	4.58%	

*The Cornerstone Investor shall not dispose of any of the Offer Shares subscribed pursuant to the cornerstone investment agreement on or before the indicated date.*

***PLACEE CONCENTRATION ANALYSIS***

<b>Places<sup>(1)</sup></b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of Shares held upon Listing<sup>(2)</sup></b>	<b>% of total issued share capital upon Listing</b>
Top 1	17,000,000	39.45%	35.51%	60,255,361	16.25%
Top 5	34,103,500	79.14%	71.23%	77,358,861	20.86%
Top 10	41,036,500	95.23%	85.71%	84,291,861	22.73%
Top 25	43,046,500	99.89%	89.90%	86,301,861	23.27%

*Notes:*

*(1) Ranking of places is based on the number of H Shares allotted to the places.*

*(2) Number of Shares held upon Listing includes existing Shares.*

***H SHAREHOLDERS CONCENTRATION ANALYSIS***

<b>H Shareholders<sup>(1)</sup></b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>% of total issued H Shares capital upon Listing</b>	<b>Number of Shares held upon Listing<sup>(2)</sup></b>
Top 1	0	0.00%	0.00%	45,937,500	23.85%	131,250,000
Top 5	17,000,000	39.45%	35.51%	116,625,539	60.56%	226,305,361
Top 10	29,113,500	67.56%	60.81%	144,948,321	75.26%	275,431,168
Top 25	39,406,500	91.45%	82.30%	182,194,340	94.60%	356,881,366

*Notes:*

*(1) Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

*(2) Number of Shares held upon Listing includes existing Shares.*

**SHAREHOLDER CONCENTRATION ANALYSIS**

<b>Shareholders<sup>(1)</sup></b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of Shares held upon Listing<sup>(2)</sup></b>	<b>% of total issued share capital upon Listing</b>
Top 1	0	0.00%	0.00%	131,250,000	35.39%
Top 5	17,000,000	39.45%	35.51%	243,910,015	65.77%
Top 10	17,000,000	39.45%	35.51%	290,150,167	78.24%
Top 25	36,543,500	84.80%	76.32%	358,779,318	96.75%

**Notes:**

*(1) Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.*

*(2) Number of Shares held upon Listing includes existing Shares.*

***BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING***

Subject to the satisfaction of the conditions set out in the Prospectus, 974 valid applications made by the public will be conditionally allocated on the basis set out below:

***Pool A:***

<b>NO. OF H SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR</b>
500	614	294 out of 614 to receive 500 Shares	47.88%
1,000	117	112 out of 117 to receive 500 Shares	47.86%
1,500	37	500 Shares plus 16 out of 37 to receive additional 500 Shares	47.75%
2,000	36	500 Shares plus 32 out of 36 to receive additional 500 Shares	47.22%
2,500	18	1,000 Shares plus 6 out of 18 to receive additional 500 Shares	46.67%
3,000	19	1,000 Shares plus 15 out of 19 to receive additional 500 Shares	46.49%
3,500	8	1,500 Shares plus 2 out of 8 to receive additional 500 Shares	46.43%
4,000	20	1,500 Shares plus 14 out of 20 to receive additional 500 Shares	46.25%
4,500	1	2,000 Shares	44.44%
5,000	23	2,000 Shares plus 10 out of 23 to receive additional 500 Shares	44.35%
6,000	5	2,500 Shares plus 1 out of 5 to receive additional 500 Shares	43.33%
7,000	2	3,000 Shares	42.86%
8,000	7	3,000 Shares plus 5 out of 7 to receive additional 500 Shares	41.96%
9,000	7	3,500 Shares plus 2 out of 7 to receive additional 500 Shares	40.48%
10,000	18	4,000 Shares	40.00%



<b>NO. OF H SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR</b>
15,000	3	6,000 Shares	40.00%
20,000	5	8,000 Shares	40.00%
25,000	3	10,000 Shares	40.00%
30,000	3	12,000 Shares	40.00%
50,000	3	20,000 Shares	40.00%
60,000	1	24,000 Shares	40.00%
70,000	1	28,000 Shares	40.00%
80,000	1	31,500 Shares	39.38%
90,000	1	35,000 Shares	38.89%
100,000	5	38,500 Shares	38.50%
200,000	4	76,500 Shares plus 3 out of 4 to receive additional 500 Shares	38.44%
300,000	5	115,000 Shares plus 3 out of 5 to receive additional 500 Shares	38.43%
400,000	3	153,500 Shares plus 1 out of 3 to receive additional 500 Shares	38.42%
Total	970	<b>Total number of Pool A successful applicants: 645</b>	

Pool B

NO. OF H SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR
500,000	1	240,000 Shares	48.00%
1,250,000	1	598,500 Shares	47.88%
1,500,000	1	718,000 Shares	47.87%
1,750,000	1	837,500 Shares	47.86%
Total	4	<b>Total number of Pool B successful applicants: 4</b>	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

**COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

**OTHERS / ADDITIONAL INFORMATION**

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a waiver and consent under Rule 9.09(b) and Rule 10.04 of the Listing Rules and Paragraph 5(2) of the Placing Guidelines allow Changxing Xingchang to subscribe for H Shares as Cornerstone Investor in the Global Offering. As more than 30% of the partnership interest of each of Huzhou Talent, Changxing Xingyin, Changxing Xinsheng, CICC Qihe, Changxing Guohai, Haibang Shuhu, Wangying Shanghe and Fuqi Investment (the existing Shareholders, collectively, the “**Zhejiang-related Entities**”) are ultimately under the supervision and management of Zhejiang Provincial People’s Government, and the Zhejiang-related Entities will in aggregate hold 43,255,361 Shares which represent approximately 11.66% of the total issued share capital of the Company upon Listing, they are regarded as core connected persons of the Company. Changxing Xingchang is an entity under the supervision and management of Changxing County People’s Government which is a county government in Zhejiang province. For the details, please refer to the section headed “Waivers from Strict Compliance with Listing Rules and Exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance – Cornerstone Subscription by Core Connected Person During the Listing Application Process”.

## **DISCLAIMERS**

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated 12 August 2024 issued by TYK Medicines, Inc for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.*

*Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – 2. Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on 20 August 2024).*

## **PUBLIC FLOAT**

Immediately following completion of the Global Offering, (i) taking into account the Conversion of 144,706,173 Unlisted Shares into H Shares to be issued and held by the Pre-IPO Investors and existing Shareholders, 93,007,501 H Shares, representing 25.08% of the total issued Shares will be held in the public hands, satisfying the minimum percentage requirement under Rule 8.08(1) of the Listing Rules; (ii) the three largest public Shareholders will not hold more than 50% of the Shares held in the public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iii) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

The Directors confirm that immediately after the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company; and (ii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company.

## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, 20 August 2024 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in “Underwriting — 2. Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. on Tuesday, 20 August 2024 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, 20 August 2024 (Hong Kong time). The H Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will be 2410.

By order of the Board  
**TYK Medicines, Inc**  
(浙江同源康醫藥股份有限公司)

**Dr. WU Yusheng**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, 19 August 2024

*As of the date of this announcement, the executive Directors are Dr. WU Yusheng and Dr. JIANG Mingyu, the non-executive Directors are Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying, Mr. HE Chao and Dr. DING Zhao, and the independent non-executive Directors are Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua.*